Regulatory overhang may dent Aurobindo Pharma earnings estimate by 15-20%

Street sentiment regarding Aurobindo Pharma — already weak on account of regulatory observations pertaining to its other facilities — has taken a further hit following the USFDA’s 14 observations to Unit IV, an injectables producing facility.  The stock, which had almost halved from the Rs 800-level between April and November 13, slumped to its five-year low before closing 8.7 per cent down on Thursday. This was despite the company putting up a decent showing in the September quarter (Q2).  Analysts say the inspections and observations surprised th.....

Key stories on are available to premium subscribers only.

Already a premium subscriber?

Subscribe to get an across device (Website, Mobile Web, Iphone, Ipad, and Android Phone applications) access to Premium content, Breaking News alerts, Industry Newsletters, Stock and Corporate news alerts, access to Archives and a lot more.